Vosoritide’s first phase 2 study shows increased growth in children with hypochondroplasia

Vosoritide’s first global phase 2 study showed an average increased growth rate of 1.8 cm per year in children with hypochondroplasia, a genetic cause of short stature in children, according to researchers from Children’s National Hospital.

Opinion | Choosing a Primary Care Specialty Should Be Lauded, Not Discouraged

Gabuzda is a fourth-year medical student. As a medical student, every time I meet a physician for the first time, I will inevitably be asked

June 22, 2024

Nuvalent: Making Precise Progress In Its Oncology Pipeline

Nuvalent, Inc. is a biotechnology company with precision-targeted treatments using kinase inhibitors for non-small cell lung cancer. NVL-520 targets ROS1-positive cancer and addresses treatment resistance,

June 27, 2024

How Intelligent Document Processing (IDP) Revolutionizes Clinical Trials

Gary Shorter – Head, AI and Data Science, IQVIA Technologies In the healthcare ecosystem, automation and data intelligence continue to gain momentum as artificial intelligence (AI) and machine learning (ML) are integrated to streamline

December 20, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.